ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2594

Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab

Christopher F Bell1, Julie Priest2,3, Marni Stott-Miller4, Hong Kan5, Justyna Amelio6, Xue Song7, Brendan Limone7, Virginia Noxon7 and Karen H. Costenbader8, 1GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, 2GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, 3US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, 4GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, 5Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 6GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, 7Truven Health Analytics, an IBM company, Ann Arbor, MI, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: administrative databases, belimumab, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. The recommended dosing regimen for intravenous belimumab is 10 mg/kg at 2-week intervals for the first 3 doses (loading dose period) and at 4-week intervals thereafter (maintenance period), for a total of 15 doses in the first year of therapy. However, in routine clinical practice, many patients may not be receiving the recommended number of loading or maintenance doses. This study evaluated the frequency of infusions in patients with SLE under routine care settings, using data from a US administrative claims database.

Methods: A retrospective analysis (study 206345) was conducted using the Truven Health MarketScan® Commercial Claims and Encounters database (Sept 01, 2010 to Dec 31, 2015). The analysis cohort comprised patients 18–64 years of age with a SLE diagnosis (ICD-9: 710.0 or ICD-10: M32) and ≥1 belimumab infusion. The index date was defined as the date patients received their first belimumab infusion. Continuous enrollment was required for 6 months pre-index and ≥3 months post-index date. The loading dose period was defined as the 34-day period post-index date; patients were divided into subgroups according to the number of infusions received in this time (1–2 or ≥3). Here we present data for those patients with 12 months of follow-up data.

Results: Overall, there were 2067 patients; the majority were female (94.7%) and had a mean (standard deviation [SD]) age of 43.9 (11.1) years. From this population, 1537 patients had 12 months of follow-up data; 877 (57.1%) received 1–2 infusions during the loading dose period and 660 (42.9%) received ≥3 infusions. The mean number of infusions and time between infusions are summarized (Table).

Conclusion: In this sample of US patients with SLE in a routine care setting, a high proportion did not receive the recommended number of belimumab loading doses. Furthermore, compared with those who completed the recommended loading dose period, patients who did not complete the loading dose period received significantly fewer belimumab infusions during the maintenance period. This study provides valuable information on belimumab treatment patterns in a real-world setting using a US claims database. These data suggest that belimumab is not always administered as recommended; the effects of this on treatment outcomes remain to be determined.

Study funded/conducted by GSK. Editorial assistance provided by Jennie McLean, PhD, of Fishawack Indicia Ltd, UK, funded by GSK.


Disclosure: C. F. Bell, GSK, 1,GSK, 3; J. Priest, GSK, 1,GSK, 3; M. Stott-Miller, GSK, 1,GSK, 3; H. Kan, GSK, 1; J. Amelio, GSK, 1,GSK, 3; X. Song, Truven Health Analytics, 3; B. Limone, None; V. Noxon, Truven Health Analytics, 3; K. H. Costenbader, Glaxo Smith Kline, 5,Merck Pharmaceuticals, 2,Biogen Idec, 5,AstraZeneca, 5.

To cite this abstract in AMA style:

Bell CF, Priest J, Stott-Miller M, Kan H, Amelio J, Song X, Limone B, Noxon V, Costenbader KH. Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/frequency-of-infusions-among-patients-diagnosed-with-systemic-lupus-erythematosus-initiating-treatment-with-intravenous-belimumab/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-infusions-among-patients-diagnosed-with-systemic-lupus-erythematosus-initiating-treatment-with-intravenous-belimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences